1077HS: Should mothers continue ART after pregnancy?

Vous êtes ici : Accueil / La Recherche / La Recherche Clinique / IMPAACT/ 1077HS

1077HS is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). 1077HS is conducted among women who received highly active antiretroviral therapy (HAART) during pregnancy for purposes of prevention of mother-to-child transmission (PMTCT) of HIV but do not otherwise meet criteria to initiate HAART for their own health. The study is designed to determine whether continuation of HAART after delivery or other pregnancy outcome reduces morbidity and mortality compared to discontinuation and re-initiation of HAART according to current standards of care.

Main Objectives:

1. To determine whether continuation of HAART (Arm A) after delivery orother pregnancy outcome educes morbidity and mortality compared todiscontinuation and re-initiation of HAART according to current standards of care (Arm B). The primary combined endpoint includesdeath, AIDS-defining illness, and serious non-AIDS-definingcardiovascular, renal, and hepatic events.

Pour plus d'information: IMPAACT Study 1077HS